Do analysts recommend AKAN or TVGN?

Tevogen Bio has a consensus price target of $100.00, indicating a potential upside of 951.52%. Given Tevogen Bio's stronger consensus rating and higher possible upside, analysts plainly believe Tevogen Bio is more favorable than Akanda. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Akanda 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Tevogen Bio 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50

Which has better earnings and valuation, AKAN or TVGN?

Tevogen Bio has lower revenue, but higher earnings than Akanda. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Akanda $260K 33.60 -$45.65M N/A N/A Tevogen Bio N/A N/A -$26.27M -$4.61 N/A

Is AKAN or TVGN more profitable?

Company Net Margins Return on Equity Return on Assets Akanda N/A N/A N/A Tevogen Bio N/A N/A -472.77%

Do analysts rate AKAN or RNXT?

RenovoRx has a consensus target price of $8.50, suggesting a potential upside of 833.35%. Given RenovoRx's stronger consensus rating and higher probable upside, analysts plainly believe RenovoRx is more favorable than Akanda. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Akanda 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 RenovoRx 1 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 1 Strong Buy rating(s) 2.75

Which has stronger valuation & earnings, AKAN or RNXT?

RenovoRx has higher revenue and earnings than Akanda. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Akanda $260K 33.60 -$45.65M N/A N/A RenovoRx $1.12M 36.67 -$11.17M -$0.33 N/A

Is AKAN or RNXT more profitable?

Akanda has a net margin of 0.00% compared to RenovoRx's net margin of -823.98%. Akanda's return on equity of 0.00% beat RenovoRx's return on equity. Company Net Margins Return on Equity Return on Assets Akanda N/A N/A N/A RenovoRx -823.98% -135.03% -101.92%

Does the media prefer AKAN or RNXT?

In the previous week, Akanda and Akanda both had 1 articles in the media. RenovoRx's average media sentiment score of 1.71 beat Akanda's score of -0.60 indicating that RenovoRx is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Akanda 0 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Negative RenovoRx 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Do analysts recommend AKAN or GRML?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Akanda 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Greenland Mines Ltd. Common Stock 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has higher valuation and earnings, AKAN or GRML?

Greenland Mines Ltd. Common Stock has lower revenue, but higher earnings than Akanda. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Akanda $260K 33.60 -$45.65M N/A N/A Greenland Mines Ltd. Common Stock N/A N/A -$10.55M -$0.32 N/A

Is AKAN or GRML more profitable?

Akanda's return on equity of 0.00% beat Greenland Mines Ltd. Common Stock's return on equity. Company Net Margins Return on Equity Return on Assets Akanda N/A N/A N/A Greenland Mines Ltd. Common Stock N/A -109.40% -98.80%

Does the media favor AKAN or GRML?

In the previous week, Greenland Mines Ltd. Common Stock had 4 more articles in the media than Akanda. MarketBeat recorded 5 mentions for Greenland Mines Ltd. Common Stock and 1 mentions for Akanda. Greenland Mines Ltd. Common Stock's average media sentiment score of 0.10 beat Akanda's score of -0.60 indicating that Greenland Mines Ltd. Common Stock is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Akanda 0 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Negative Greenland Mines Ltd. Common Stock 0 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts prefer AKAN or BGM?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Akanda 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 BGM Group 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has stronger earnings & valuation, AKAN or BGM?

BGM Group has higher revenue and earnings than Akanda. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Akanda $260K 33.60 -$45.65M N/A N/A BGM Group $26.85M 1.24 -$1.44M N/A N/A

Is AKAN or BGM more profitable?

Company Net Margins Return on Equity Return on Assets Akanda N/A N/A N/A BGM Group N/A N/A N/A

Which has preferable earnings & valuation, BTAI or AKAN?

Akanda has lower revenue, but higher earnings than BioXcel Therapeutics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio BioXcel Therapeutics $640K 60.80 -$69.90M -$5.75 N/A Akanda $260K 33.60 -$45.65M N/A N/A

Is BTAI or AKAN more profitable?

Akanda has a net margin of 0.00% compared to BioXcel Therapeutics' net margin of -11,078.53%. Company Net Margins Return on Equity Return on Assets BioXcel Therapeutics -11,078.53% N/A -201.53% Akanda N/A N/A N/A

Akanda (AKAN) Competitors

$16.18 +1.11 (+7.37%)

Closing price 06/23/2026 04:00 PM Eastern

Extended Trading

$15.63 -0.55 (-3.40%)

As of 06/23/2026 07:57 PM Eastern

Compare

AKAN vs. TVGN, RNXT, GRML, BGM, and BTAI

Should you buy Akanda stock or one of its competitors? MarketBeat compares Akanda with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Akanda include Tevogen Bio (TVGN), RenovoRx (RNXT), Greenland Mines Ltd. Common Stock (GRML), BGM Group (BGM), and BioXcel Therapeutics (BTAI). These companies are all part of the "pharmaceutical products" industry.

How does Akanda compare to Tevogen Bio?

Akanda (NASDAQ:AKAN) and Tevogen Bio (NASDAQ:TVGN) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their earnings, media sentiment, valuation, dividends, profitability, analyst recommendations, institutional ownership and risk.

Akanda has a beta of 14.02, indicating that its share price is 1,302% more volatile than the broader market. Comparatively, Tevogen Bio has a beta of 0.14, indicating that its share price is 86% less volatile than the broader market.

Tevogen Bio has lower revenue, but higher earnings than Akanda.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Akanda	$260K	33.60	-$45.65M	N/A	N/A
Tevogen Bio	N/A	N/A	-$26.27M	-$4.61	N/A

Company	Net Margins	Return on Equity	Return on Assets
Akanda	N/A	N/A	N/A
Tevogen Bio	N/A	N/A	-472.77%

1.0% of Akanda shares are held by institutional investors. 20.4% of Akanda shares are held by insiders. Comparatively, 70.5% of Tevogen Bio shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Tevogen Bio has a consensus price target of $100.00, indicating a potential upside of 951.52%. Given Tevogen Bio's stronger consensus rating and higher possible upside, analysts plainly believe Tevogen Bio is more favorable than Akanda.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Akanda	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Tevogen Bio	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50

In the previous week, Akanda had 1 more articles in the media than Tevogen Bio. MarketBeat recorded 1 mentions for Akanda and 0 mentions for Tevogen Bio. Tevogen Bio's average media sentiment score of 0.00 beat Akanda's score of -0.60 indicating that Tevogen Bio is being referred to more favorably in the news media.

Company	Overall Sentiment
Akanda	Negative
Tevogen Bio	Neutral

Summary

Akanda and Tevogen Bio tied by winning 5 of the 10 factors compared between the two stocks.

How does Akanda compare to RenovoRx?

Akanda (NASDAQ:AKAN) and RenovoRx (NASDAQ:RNXT) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, analyst recommendations, profitability, risk, dividends, earnings, media sentiment and valuation.

Akanda has a net margin of 0.00% compared to RenovoRx's net margin of -823.98%. Akanda's return on equity of 0.00% beat RenovoRx's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Akanda	N/A	N/A	N/A
RenovoRx	-823.98%	-135.03%	-101.92%

RenovoRx has a consensus target price of $8.50, suggesting a potential upside of 833.35%. Given RenovoRx's stronger consensus rating and higher probable upside, analysts plainly believe RenovoRx is more favorable than Akanda.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Akanda	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
RenovoRx	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.75

In the previous week, Akanda and Akanda both had 1 articles in the media. RenovoRx's average media sentiment score of 1.71 beat Akanda's score of -0.60 indicating that RenovoRx is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Akanda	0 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Negative
RenovoRx	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

1.0% of Akanda shares are held by institutional investors. Comparatively, 3.1% of RenovoRx shares are held by institutional investors. 20.4% of Akanda shares are held by company insiders. Comparatively, 9.4% of RenovoRx shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Akanda has a beta of 14.02, indicating that its share price is 1,302% more volatile than the broader market. Comparatively, RenovoRx has a beta of 1.01, indicating that its share price is 1% more volatile than the broader market.

RenovoRx has higher revenue and earnings than Akanda.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Akanda	$260K	33.60	-$45.65M	N/A	N/A
RenovoRx	$1.12M	36.67	-$11.17M	-$0.33	N/A

Summary

RenovoRx beats Akanda on 9 of the 14 factors compared between the two stocks.

How does Akanda compare to Greenland Mines Ltd. Common Stock?

Akanda (NASDAQ:AKAN) and Greenland Mines Ltd. Common Stock (NASDAQ:GRML) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, analyst recommendations, profitability, valuation, risk, earnings, media sentiment and dividends.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Akanda	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Greenland Mines Ltd. Common Stock	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

In the previous week, Greenland Mines Ltd. Common Stock had 4 more articles in the media than Akanda. MarketBeat recorded 5 mentions for Greenland Mines Ltd. Common Stock and 1 mentions for Akanda. Greenland Mines Ltd. Common Stock's average media sentiment score of 0.10 beat Akanda's score of -0.60 indicating that Greenland Mines Ltd. Common Stock is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Akanda	0 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Negative
Greenland Mines Ltd. Common Stock	0 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Akanda has a beta of 14.02, indicating that its stock price is 1,302% more volatile than the broader market. Comparatively, Greenland Mines Ltd. Common Stock has a beta of 6.94, indicating that its stock price is 594% more volatile than the broader market.

Greenland Mines Ltd. Common Stock has lower revenue, but higher earnings than Akanda.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Akanda	$260K	33.60	-$45.65M	N/A	N/A
Greenland Mines Ltd. Common Stock	N/A	N/A	-$10.55M	-$0.32	N/A

Akanda's return on equity of 0.00% beat Greenland Mines Ltd. Common Stock's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Akanda	N/A	N/A	N/A
Greenland Mines Ltd. Common Stock	N/A	-109.40%	-98.80%

1.0% of Akanda shares are held by institutional investors. Comparatively, 20.1% of Greenland Mines Ltd. Common Stock shares are held by institutional investors. 20.4% of Akanda shares are held by company insiders. Comparatively, 11.3% of Greenland Mines Ltd. Common Stock shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Summary

Akanda beats Greenland Mines Ltd. Common Stock on 5 of the 9 factors compared between the two stocks.

How does Akanda compare to BGM Group?

Akanda (NASDAQ:AKAN) and BGM Group (NASDAQ:BGM) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, media sentiment, risk, analyst recommendations, institutional ownership, profitability, valuation and earnings.

Akanda has a beta of 14.02, indicating that its share price is 1,302% more volatile than the broader market. Comparatively, BGM Group has a beta of 1.81, indicating that its share price is 81% more volatile than the broader market.

In the previous week, Akanda had 1 more articles in the media than BGM Group. MarketBeat recorded 1 mentions for Akanda and 0 mentions for BGM Group. BGM Group's average media sentiment score of 0.00 beat Akanda's score of -0.60 indicating that BGM Group is being referred to more favorably in the news media.

Company	Overall Sentiment
Akanda	Negative
BGM Group	Neutral

1.0% of Akanda shares are held by institutional investors. 20.4% of Akanda shares are held by insiders. Comparatively, 58.7% of BGM Group shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Company	Net Margins	Return on Equity	Return on Assets
Akanda	N/A	N/A	N/A
BGM Group	N/A	N/A	N/A

BGM Group has higher revenue and earnings than Akanda.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Akanda	$260K	33.60	-$45.65M	N/A	N/A
BGM Group	$26.85M	1.24	-$1.44M	N/A	N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Akanda	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
BGM Group	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

Akanda and BGM Group tied by winning 4 of the 8 factors compared between the two stocks.

How does Akanda compare to BioXcel Therapeutics?

BioXcel Therapeutics (NASDAQ:BTAI) and Akanda (NASDAQ:AKAN) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, media sentiment, analyst recommendations, dividends, profitability, valuation, risk and earnings.

30.7% of BioXcel Therapeutics shares are held by institutional investors. Comparatively, 1.0% of Akanda shares are held by institutional investors. 3.7% of BioXcel Therapeutics shares are held by company insiders. Comparatively, 20.4% of Akanda shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

In the previous week, Akanda had 1 more articles in the media than BioXcel Therapeutics. MarketBeat recorded 1 mentions for Akanda and 0 mentions for BioXcel Therapeutics. BioXcel Therapeutics' average media sentiment score of 0.00 beat Akanda's score of -0.60 indicating that BioXcel Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
BioXcel Therapeutics	Neutral
Akanda	Negative

Akanda has lower revenue, but higher earnings than BioXcel Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BioXcel Therapeutics	$640K	60.80	-$69.90M	-$5.75	N/A
Akanda	$260K	33.60	-$45.65M	N/A	N/A

Akanda has a net margin of 0.00% compared to BioXcel Therapeutics' net margin of -11,078.53%.

Company	Net Margins	Return on Equity	Return on Assets
BioXcel Therapeutics	-11,078.53%	N/A	-201.53%
Akanda	N/A	N/A	N/A

BioXcel Therapeutics currently has a consensus price target of $11.00, suggesting a potential upside of 773.02%. Given BioXcel Therapeutics' stronger consensus rating and higher possible upside, equities research analysts clearly believe BioXcel Therapeutics is more favorable than Akanda.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BioXcel Therapeutics	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
Akanda	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

BioXcel Therapeutics has a beta of 0.3, meaning that its share price is 70% less volatile than the broader market. Comparatively, Akanda has a beta of 14.02, meaning that its share price is 1,302% more volatile than the broader market.

Summary

BioXcel Therapeutics beats Akanda on 7 of the 13 factors compared between the two stocks.

Get Akanda News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding AKAN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

AKAN vs. The Competition

Export

Metric	Akanda	MED PRODUCTS Industry	Medical Sector	NASDAQ Exchange
Market Cap	$8.15M	$8.08B	$6.44B	$12.39B
Dividend Yield	N/A	2.59%	2.69%	5.83%
P/E Ratio	N/A	15.24	24.66	23.99
Price / Sales	33.60	6.99	528.64	107.77
Price / Cash	N/A	16.83	44.82	54.51
Price / Book	-0.63	3.21	10.79	6.50
Net Income	-$45.65M	$226.25M	$3.56B	$336.88M
7 Day Performance	-14.84%	-1.89%	1.01%	-0.14%
1 Month Performance	-40.34%	-3.72%	0.43%	0.77%
1 Year Performance	-80.90%	-1.12%	29.71%	28.49%

Akanda Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
AKAN Akanda	0.3083 of 5 stars	$16.18 +7.4%	N/A	-81.4%	$8.15M	$260K	N/A	110	Gap Down
TVGN Tevogen Bio	1.8799 of 5 stars	$9.70 +6.0%	$100.00 +930.9%	-83.6%	$40.39M	N/A	N/A	3
RNXT RenovoRx	4.1215 of 5 stars	$0.89 +1.3%	$8.50 +854.3%	-35.4%	$40.17M	$1.12M	N/A	6	News Coverage Positive News Gap Down
GRML Greenland Mines Ltd. Common Stock	0.4593 of 5 stars	$0.32 -1.2%	N/A	-78.7%	$38.71M	N/A	N/A	5	Gap Down
BGM BGM Group	0.4364 of 5 stars	$0.39 -12.6%	N/A	-97.4%	$37.74M	$26.85M	N/A	298

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:AKAN) was last updated on 6/24/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Akanda (AKAN) Competitors